Those taking the 15 mg dose in SURMOUNT-1 had weight reductions of up to 22.5 percent throughout the course of the 72-week research, with more than 60% of those on the 15 mg dose seeing weight reductions of 20% or more. A measuring tape is linked to a scale. In the SURMOUNT-1 research, there was a link between tirzepatide use and weight reduction of up to 22.5 percent of a patient’s body weight.
The trial met both of its coprimary goals of superior mean percent change in body weight from baseline and a higher percentage of persons achieving weight reductions of at least 5% compared to placebo medicine, as well as all critical secondary endpoints, according to Eli Lilly and Company. “Obesity is a chronic disease that often does not receive the same standard of care as other conditions,” said Dr. Louis J. Aronne of Weill Cornell Medicine’s Comprehensive Weight Control Center and the Sanford I. Weill Professor of Metabolic Research, despite the impact it has on one’s physical, psychological, and metabolic health, including an increased risk of hypertension, heart disease, cancer, and a shorter lifespan.
“Tirzepatide provided remarkable body weight reductions in SURMOUNT-1,” according to patients and clinicians working cooperatively to manage this difficult disease. The SURMOUNT-1 study has swiftly achieved popularity as one of the most anxiously expected investigations into obesity in recent years, thanks to the encouraging outcomes of tirzepatide in the SURPASS research. In a multicenter, randomized, double-blind, parallel, placebo-controlled trial, SURMOUNT-1 enrolled 2,539 obese or overweight adult patients without type 2 diabetes who also had high blood pressure, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. A placebo was used to compare Tirizepatide 5 mg, 10 mg, and 15 mg.
A press statement from Eli Lilly and Company
individuals who took the 5 mg, 10 mg, and 15 mg versions of tirzepatide lost 16 percent (16 kg), 21.4 percent (22 kg), and 22.5 percent (24 kg) more weight than those who took the placebo. In the tirzepatide 5 mg and 10 mg arms, at least 89 percent of patients dropped at least 5% of their body weight. Only 28% of participants in the placebo group lost at least 5% of their body weight. According to the press release, 55 percent of individuals receiving tirzepatide 10 mg and 63 percent of those on tirzepatide 15 mg lost 20% or more of their body weight, while only 1% of those taking a placebo lost 20% or more of their body weight.
The safety of Tirzepatide was determined by examining the most frequently reported adverse effects, which were all gastrointestinal in character and mild to moderate in severity. The majority of these side events occurred during the dose-escalation phase of the experiment. The tirzepatide arms had higher nausea, diarrhea, commitment, and constipation than the placebo arms. Thirteen percent of patients on tirzepatide 5 mg stopped taking it, sixteen percent stopped taking tirzepatide 10 mg, fifteen percent stopped taking tirzepatide 15 mg, and twenty-six percent stopped taking placebo.
According to Jeff Emmick, MD, Ph.D., vice president of product development at Eli Lilly and Company, “Tirzepatide is the first investigational medication to provide more than 20% weight loss on average” in a phase 3 study. Lilly is working relentlessly to support those who are impacted by obesity and to improve the way the disease is treated.” People who had pre-diabetes at the start of SURMOUNT-1 will be followed for an additional 104 weeks to see how tirzepatide affects body weight and whether it reduces the progression of diabetes over three years when compared to placebo.
Tirzepatide lose 16 percent or more of their body weight
According to the topline results of the SURMOUNT-1 clinical trial, patients receiving the once-weekly GIP/GLP-1 receptor agonist tirzepatide lost at least 16 percent of their body weight. Rizeptadine (Eli Lilly) met both primary objectives of a phase 3 trial with 2,539 participants, including the mean percentage change in body weight from baseline and the percentage of patients who dropped 5% of their body weight above placebo. Adults who were administered 5 mg, 20 mg, or 15 mg of tirzepatide lost an average of 16 percent of their body weight, compared to only 2% of those who were given a placebo.
Louis J. Aronne, the Sanford I. Weill Professor of Metabolic Research at Weill Cornell Medicine, said in a news statement reported by Healio that “this study demonstrates that highly considerable weight loss can be attained with tirzepatide, in accordance with what is done with surgical therapies.” After starting with a BMI of 38 kilograms per square meter, it reduced to 30 kilograms per square meter, with several people falling within the normal range.
All secondary goals were fulfilled with Tirzepatide, with 55 percent of those taking 10 mg and 63 percent of those on 15 mg losing at least 20% of their body weight, compared to 1% of those on placebo. According to the press release, a secondary endpoint analysis that did not account for type 1 error indicated that 32 percent of persons taking 5 mg tirzepatide lost at least 20% of their body weight.
“To put things in perspective, a 5% weight loss reduces diabetes risk by 50%, and a 10% weight loss reduces it by 80%,” Aronne said. Sleeve gastrectomy results in a 25% weight loss, while lap band surgery results in a 17% weight loss. Bariatric surgery and diets are not mutually exclusive. The void is being filled by medical therapy.” Other incretin-based medications with similar safety and tolerance characteristics as tirzepatide were approved for the treatment of obesity. Nausea, diarrhea, constipation, and vomiting were the most common side effects, all of which were mild to moderate.
BACKGROUND
Tirzepatide, a dual GLP-1, and insulinotropic polypeptide agonist is now in clinical studies for the treatment of type 2 diabetes. The effectiveness and safety of tirzepatide in the presence of semaglutide, a GLP-1 receptor agonist, are unknown. After the initial 72 weeks, trial participants with prediabetes will be monitored for a total of 104 weeks to examine if there are any differences in type 2 diabetes progression with tirzepatide versus placebo, as well as the impact of weight increase. According to the release, the results of SURMOUNT-1 will be presented at a medical symposium and submitted to a peer-reviewed publication. Right now, more study is being carried out.
Discussion
Tirzepatide at doses of 5 mg, 10 mg, or 15 mg was found to be as effective as semaglutide at a dose of 1 mg in decreasing glycated hemoglobin levels in patients with type 2 diabetes on metformin. Tirzepatide was also superior to semaglutide in terms of weight loss. Patients receiving tirzepatide or semaglutide should have a glycated hemoglobin level of less than 7.0 percent, according to the American Diabetes Association and the European Association for the Study of Diabetes, and both treatments were effective for 82 to 86 percent of patients and 79 percent of patients, respectively.
21 27 to 46 percent of patients treated with tirzepatide and 19 percent of patients treated with semaglutide attained a glycated hemoglobin level of less than 5.7 percent (normoglycemia). Patients given 15 mg of tirzepatide lost almost twice as much weight as those given 1 mg of semaglutide. The weight decrease in any of the four therapy groups did not halt after 40 weeks.
